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Summary 
Treatment for primary membranous nephropathy has remains still cyclophosphamide-based 
(the Ponticelli regimes), since the 1980s despite its high side-effect burden.  Newer therapies 
such as Rituximab show promise but are expensive.  We undertook a cost-effectiveness 
analysis of overall administration costings; based on UK NHS prices to compare Rituximab with 
than the modified Ponticelli regime, the current standard of care.  
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Background 
Membranous Nephropathy is among the most common causes of nephrotic syndrome 
worldwide, with a high healthcare burden. Treatment using the modified Ponticelli regimes 
(mPR) has remained the standard of care for decades, but newer therapies such as Rituximab 
offer promising results with reduced side effects. The cost of this treatment however, is 
perceived as a barrier to widespread use; especially in resource limited healthcare systems. 
 
Methods 
We developed a decision-analytic model to estimate the cost-effectiveness of Rituximab 
versus the mPR from the perspective of the National Health Service in the UK over a one-year, 
five-year and lifetime horizon. Primary outcome is the cost-effectiveness of Rituximab vs. mPR 
at five-years post-treatment.  Secondary outcomes are cost-effectiveness at 1 and 10 years 
post-treatment and over a lifetime.  
 
Results 
At one-year post-treatment, Rituximab therapy dominates mPR.  At five-years post treatment, 
Rituximab therapy is cheaper than the Ponticelli regime but at a loss of 0.014 QALYs with an 
ICER of £95,494.13.  Over a lifetime, Rituximab remains the cheaper option with an 
incremental cost of -£5251.03 but with a reduced quality of life (incremental QALY of -0.512) 
giving an ICER of £10,246.09.  
 
Conclusions 
Our analysis indicates that Rituximab has the potential to be a cost-effective treatment in the 
short and medium term despite the high single dose cost.  This evaluation suggests that 
further research is warranted and highlights the need for a high quality clinical trial to confirm 
the efficacy and cost-effectiveness of Rituximab versus the current standard of care. 
 
 
  
  3 
Introduction  
Membranous nephropathy (MN) is one of the most common causes of adult nephrotic 
syndrome worldwide with a high healthcare burden in which approximately 20% of patients 
progress to end stage renal disease (ESRD)1,2. 
MN has two distinct entities with primary MN (PMN) now considered to be an autoimmune 
disease since the discovery of the M-type of phospholipase A2 receptor 1 (anti-PLA2R) 
antibodies3-7.  
In PMN, disease activity and prognosis is still measured by proteinuria level and renal 
excretory function with the risk of renal decline falling in the presence of a reduction in 
proteinuria6,10-14.  A key marker of treatment efficacy in PMN is therefore control of 
proteinuria, with or without immunosuppression9.  Such immunosuppression is generally a 
combination of alkylating agents and steroids, as used in studies by Ponticelli et al15-18.  This 
regime of rotating high dose intravenous steroids and immunosuppression was first described 
in 1984 and has been the mainstay of treatment since15.  Initially using Methylprednisolone 
and Chlorambucil, it was later modified to include Methylprednisolone and 
Cyclophosphamide15-18.  Despite its treatment success, the modified Ponticelli regime (mPR) 
bares a significant side effect profile, including an increased risk of infection, osteoporosis, 
diabetes mellitus, weight gain, haemorrhagic cystitis, infertility and malignancy16.  This led 
many researchers to search for alternative therapies including tacrolimus and Mycophenolate 
Mofetil but with little evidence to show any improvement in outcomes19-23.   
Rituximab has been used extensively in cancer therapy since the late 1990s and more recently 
for autoimmune diseases.  A number of case series and studies have demonstrated potential 
in PMN but so far randomised controlled trials (RCT) have been scarce24-28.    This, combined 
with the high cost of the medication itself, has restricted its widespread use in resource 
limited, evidence based, healthcare systems such as the National Health Service in the UK 
(NHS).   
We developed a decision-analytic model to estimate the cost-effectiveness of Rituximab 
therapy versus the standard of care, namely the modified Ponticelli regime for the treatment 
of primary MN. 
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Methods  
A cost-effectiveness analysis was carried out using a stochastic cohort Markov model 
developed using standard methods29, conducted from the perspective of current practice in 
the UK NHS at 2015 prices. 
The primary outcome was the cost-effectiveness of Rituximab versus mPR at five-years post 
treatment.  Secondary outcomes were cost-effectiveness at one and ten years post-treatment 
and over a lifetime. A literature search revealed no studies directly comparing Rituximab 
versus mPR and therefore data was taken from the only studies of sufficient size to afford 
representative outcome assessment as described below. The analysis employed the cost-
utility framework where the main measure of benefit is the quality-adjusted life year (QALY) 
and with analysis outcomes presented in terms of incremental cost-effectiveness ratios (ICER) 
of cost per QALY gained.  
 
Choice of comparator 
Here we have used the mPR which is the standard of treatment as per the KDIGO guidelines 
having established that the majority of UK renal centres use versions of the mPR as described 
by Ponticelli et al and Jha et al9,17,18,30.   
 
Model Structure  
The model was developed in consultation with an expert panel including physicians, health 
economists and clinical scientists, and was identical for each treatment arm (see figure 1). 
For the treatment phase, all patients were assumed to experience active disease and costs 
were calculated from the papers described below.  Following the treatment phase, patients 
could transition to (persistent) active disease, partial remission or complete remission.  Health 
states then included sustained remission, relapse, ESRD (conservative management, haemo- 
or peritoneal dialysis and renal transplant) or death.  Following the initial treatment phase, 
patients transitioned between health states on three-monthly cycles over a lifetime horizon. 
PMN is generally considered a disease of middle age with the median age of patients with 
PMN at diagnosis is 53 years old; we therefore extended the lifetime over an additional 47 
years corresponding to a maximum survival of 100 years old31.   
 
 
 
Parameter values 
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Model parameter values and effectiveness of the interventions were based on the most 
robust data available for each arm; Jha et al for the mPR arm and Ruggenenti et al for the 
Rituximab arm18,26.  Jha et al was a prospective RCT comparing the mPR with supportive care, 
in biopsy proven adults (>16 years old) with nephrotic syndrome for more than 6 months 
duration and less than 2 months of treatment with either steroids or immunosuppression.  
There was a total of 93 patients completing the study, 47 receiving the mPR with oral 
cyclophosphamide and IV Methylprednisolone.   
Ruggenenti et al published an observational study describing 100 consecutive patients, 
considered to be at a high risk of progressing to ESRD or to develop significant cardiovascular 
complications of their nephrotic syndrome, treated with Rituximab and no control group. It 
involved two distinct regimes; initially patients received Rituximab in four weekly doses of 
375mg/m2.  However, as many patients on this regime were found to be B cell deplete after 
only the first dose of Rituximab, all subsequent patients from 2005 onwards were changed to 
a titrated regime.  Prior to inclusion in the trial, 32 patients had received treatment with 
alternative immunosuppression.  20 of these did achieve partial remission prior to relapsing 
and necessitating treatment.  The remaining 12 never achieved remission prior to starting 
Rituximab.  Of the 100 patients described in the study, 71 received a single 375mg/m2 dose of 
Rituximab and only received a second dose if their serum B cells were more than 5 cells/mm3. 
The cost of treatment in the Rituximab arm was therefore calculated using the same 
proportion of treatments (with corresponding outcomes) as in this study.  This resulted in 29% 
of the total cost of treatment being taken as the cost of the initial four doses of 375mg/m2 
Rituximab regime and 71% as the cost of the B-cell titration regime. 
These papers were also chosen for their similar observational period allowing for a similar 
evaluation of care; however partial and complete remission were defined slightly differently 
(table 1), Jha et al having more stringent remission criteria.  In practice, there is a cohort of 
patients that spontaneously remit but the majority will remain nephrotic and therefore 
require treatment.  Both these studies, as in clinical practice, have included patients with 
biopsy proven membranous nephropathy and significant proteinuria warranting 
immunosuppression.  Both studies have a male predominance reflecting clinical practice and 
the mean age at presentation was older in the study as described by Ruggenenti et al.  Jha et 
al was carried out in India and Ruggenenti et al was carried out in Italy, two differing 
healthcare systems.  However, both studies were carried out using standard methods and are 
comparable to use in the UK18,26.  See table 1. 
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Probabilities 
Transition probabilities from the treatment phase to active disease, complete remission, 
partial remission, relapse and death were taken from the literature as above (Jha et al and 
Ruggenenti et al18,26).  Here there was an assumption of constant hazards based on survival at 
a single time point.  If a patient developed ESRD they transitioned into the renal replacement 
pathway, which includes conservative management. Transition probabilities after ESRD have 
been obtained from the UK Renal Registry (2014)32.  Death rates were taken as those 
described in the study arms.  At the end of the study follow up, UK Office of National Statistics 
(ONS) data was used to provide a baseline mortality rate33.  For patients in active disease, the 
death rate obtained from the ONS data was added to the transition probability from the 
studies.  Once in partial or complete remission, death rate was taken as that in the ONS only.  
Death rates once in ESRD were taken from the UK Renal Registry.   
 
Costs 
Healthcare resource use included all healthcare contact, hospital stays, medication and 
serious adverse event (SAEs) episodes described in each publication.  The cost of relapse was 
taken as the cost of treatment but without SAEs.  Costs for each hospital/healthcare contact 
and SAEs were taken from the NHS reference costs 2014 to 201534.  Standard Deviation 
estimated using S = Q3 WQ1 / 1.35 35.  The cost of medication was taken from the Drugs and 
Pharmaceutical electronic market information (eMit) or from the British National Formulary 
2015 if not available36,37.  For medications for which the dose is based on Body Surface Area 
we used 1.79m2  38.  Maintenance therapy was not costed.  Standard deviation of costs is not 
provided by the BNF so these were taken to be half the mean. (Table 2, 3 & 4).  See 
supplementary material for table with disaggregated costs of treatment stage for reference 
case and regimes used in sensitivity analysis. 
 
 
Utility/Quality of life 
For many patients, the presenting symptoms that bring them to the notice of healthcare 
professionals, and ultimately to the diagnosis of PMN, is that of the nephrotic syndrome, 
namely oedema, increasing shortness of breath and fatigue.  Currently there is limited data 
available on the quality of life (or utility) for patients with PMN, therefore utility values for 
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active disease were taken as that of active nephrotic syndrome, given these are the main 
symptoms a patient will experience when their disease is active39.  For patients with partial or 
complete remission we used age and sex matched EQ-5D UK population norms40.  Once 
patients reached ESRD, utility values were estimated using SF-6D values from Wyld et al. 
converted to utility scores41,42. (Table 5). 
 
Cost-effectiveness analysis 
All costs are presented as mean cost per patient. Expected costs and QALYs were estimated 
for each arm and, where appropriate, ICERs calculated (derived from the incremental cost of 
treating with Rituximab and the incremental QALY).  ICERs below the £20,000 threshold would 
indicate that Rituximab is considered cost-effective as set by National Institute for Health and 
Care Excellence (NICE) standards43. Following NICE guidelines, half cycle correction was 
conducted and a discount rate of 3.5% per annum was applied to all outcomes incurred 
beyond one year43.  
 
Incremental Net Monetary Benefit (INMB) 
/ED ?ƐǁĞƌĞĐĂůĐƵůĂƚĞĚƵƐŝŶŐƚŚĞŝŶĐƌĞŵĞŶƚĂůY>z ?ƚŚĞŝŶĐƌĞŵĞŶƚĂůĐŽƐƚĂŶĚƚŚĞ>ĂŵďĚĂ ?
which in this case is £20,000, as per NICE guidelines43.  A positive value indicates that 
Rituximab therapy is cost effective and therefore the preferred option when compared with 
the mPR.   
 
Deterministic Sensitivity Analysis 
We performed one-way sensitivity analysis on a range of parameters to assess the impact of 
each parameter on the outcome of the model at five-years post treatment as described by 
the INMB. For sensitivity analysis of the costs, these were altered, the quality of life and 
transition probabilities remaining unchanged.  For sensitivity analysis of the transition 
probabilities, the costs remained unchanged.  Exact alterations to costs and probabilities are 
given below. 
 
Rituximab regimes 
The study described by Ruggenenti et al used to inform the Rituximab arm in our model 
utilised two different regimes as described in the methods section.  We therefore carried out 
a sensitivity analysis based on all patients in the Rituximab arm receiving the original regime 
consisting of four weekly infusions of 375mg/m2 Rituximab.  We then carried out the analysis 
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based on all patients in the Rituximab arm receiving the B cell titrated regime ie a single 
375mg/m2 dose of Rituximab with a second dose if their serum B cells were subsequently 
more than 5 cells/mm3.  For both of these, the costs in the Ponticelli arm remained unchanged.  
Further sensitivity analysis was carried out using the recently reported RCT described by 
Dahan et al27.  Here patients in the treatment arm were given 2 doses of 375mg/m2 Rituximab 
on days 1 and 8.  For this analysis, only the costs in Rituximab arm of the model were changed 
and all outcomes remained the same. 
 
Ponticelli regimes 
The mPR uses low cost medications but requires multiple hospital admissions to receive 
steroid infusions.  Therefore, to assess the impact that drug delivery has on the overall cost 
we performed a sensitivity analysis with patients only receiving oral prednisolone and no IV 
Methylprednisolone, with cyclophosphamide remaining unchanged.  We also assessed how a 
change in the cyclophosphamide regime may affect the overall cost by carrying out a 
sensitivity analysis using pulsed monthly cyclophosphamide for 6 months with adjunctive oral 
prednisolone (with no IV methylprednisolone) as described by Kanigicherla et al44.  The costs 
for the Rituximab arm remained unchanged for both of these analyses.    
 
Other 
To assess how the cost of drug delivery itself affects the model outcomes we performed a 
sensitivity analysis with an increase and decrease in the cost of the delivery of an infusion in 
a day-care setting by 20% and on the cost of the medication itself (Rituximab and 
Cyclophosphamide).  For the cost of infusion delivery, the cost was altered in both arms.  For 
the cost of medication, the cost was altered in each arm and analysed separately. 
In order to provide consistency, the cost of cancer in the original analysis was taken as the 
cost for the least severe form of the disease as per the NHS reference costs34.  To assess 
whether the cost of cancer impacts on the results we used the cost for the most severe form 
of the various cancers as reported in the NHS reference costs34 for the sensitivity analysis. 
Given the known uncertainty in the quality of life measures available we performed a 
sensitivity analysis on this by altering the utility value of partial remission to be the same as 
active disease instead of complete remission.  This was changed in both arms simultaneously. 
 
Transition probabilities 
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To investigate the impact of the transition probabilities on outcomes, we performed a number 
of analysis including altering the death rate to be equal in both arms, the chance of developing 
ESRD and needing RRT to be equal in both arms and the rate of relapse to be equal in both 
arms.  We analysed the effect of treatment efficacy by altering the transition probabilities of 
going from the treatment phase to either active disease, partial remission or complete 
remission by making them equal in both arms.  We then altered the chance of transitioning 
from active disease to remission so that it was equal in both arms.  We altered all transition 
probabilities to be equal in both arms with no change to costs or utility values.  We also 
increased and decreased the probability, by 20%, of going into remission in the Rituximab arm 
and keeping the Ponticelli arm unchanged.  We then performed the same analysis by altering 
the transition probability in the Ponticelli arm and kept the Rituximab arm unchanged.   
 
Probabilistic Sensitivity Analysis 
A probabilistic sensitivity analysis (PSA) was conducted with 10,000 Monte Carlo simulations 
based on random draws of all parameter values simultaneously from probability distributions. 
This provided 10,000 estimates of costs and QALYs, which were used to generate 10,000 ICERs 
and incremental net monetary benefit (INMB) estimates and allowed us to estimate the level 
of parameter uncertainty in the analysis. These simulated analyses were plotted on a cost-
effectiveness plane and a cost-effectiveness acceptability curve (CEAC)45. The CEAC indicates 
the probability that Rituximab is cost-effective versus mPR across a range of willingness to pay 
per QALY gain thresholds46. The higher the probability, the lower the uncertainty is in the 
model and decision. 
 
Validation 
We employed a number of tests to ensure the model was valid as possible although given the 
nature of the disease and lack of clinical trials, we were unable to perform a full 
validation.  Validation was carried out using recognised techniques47.  Face validation was 
carried out with each aspect of the model design, data sources, formulae and eventual results 
reviewed and discussed by a panel of experts including clinicians, clinical scientists and health 
economists.  Internal validation was performed using deterministic sensitivity analysis and 
testing whether changes in model inputs led to changes in outputs in the expected direction 
- for example by increasing the SAE / AE risks for Rituximab we expected the cost-effectiveness 
of that intervention would be reduced.  Verification of the code was performed by one 
clinician and two separate and independent health economists. 
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As there are no other health economic or epidemiological models or RCTs in this area, cross 
validation, external validation and predictive validation were not possible. 
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Results 
Incremental Cost-Effectiveness Ratio 
At five-years post treatment, Rituximab therapy is cheaper than the Ponticelli regime but at a 
loss of 0.014 QALYs.  Here the ICER is £95,494.13 (incremental cost -£1,355.82 and 
incremental QALY -0.014).  At one-year post-treatment, Rituximab therapy dominates mPR.  
At 10 years post-treatment, Rituximab remains the cheaper option with an incremental cost 
of -£2,201.37.  With an incremental QALY of -0.091 the ICER is £24,256.91.  Over a lifetime the 
ICER was £10,246.09, obtained from the incremental per-patient cost of -£5,251.03 and 
incremental QALY of -0.512.  See supplementary material for frequency of patients in each 
disease state at five-years post-treatment with corresponding costs and QALYs.  See table 6. 
 
Figure 2 - cost-effectiveness plane showing incremental costs versus incremental QALY at one-
year, five-year and over a lifetime. Threshold line at £20,000 per QALY for 10,000 PSA 
simulations.  At one-year and five-year post treatment the majority of simulated ICERs are in 
the right-hand side of the plane indicating Rituximab is more effective.  There is a majority of 
patients in the lower half of the plane indicating that at five-years post treatment, Rituximab 
therapy is cheaper.  The vast majority are below the £20,000 per QALY threshold set by NICE 
as the acceptable limit for the cost-effectiveness43.  Over a lifetime the majority of patients 
are in the left lower quadrant showing that Rituximab therapy is cheaper but less effective. 
 
Cost 
At five-years post treatment the cost for the mPR was -£13,116.65 and the cost for the 
Rituximab regime was £11,760.83, showing that the mPR is more expensive than Rituximab 
with an incremental cost of -£1,355.82.  At one-year post-treatment, the cost of mPR and 
Rituximab was £8,676.10 and £7,927.90 respectively giving and incremental cost of -£748.20.  
At ten-years post-treatment, the cost of mPR was £17,834.30 and for Rituximab was 
£15,632.93, indicating that Rituximab continues to be cheaper with an incremental cost of -
£2,201.37.  Over a lifetime the cost of mPR is £29,943.80 compared to £24,692.77 for the 
mPR; an incremental cost of -£5,251.03. See table 6.  
 
QALY 
The QALY gains for mPR and Rituximab were 3.712 and 3.697 respectively at five-years post 
treatment, 0.952 and 0.954 respectively at one-year, 6.603 and 6.513 respectively at ten-
years, and 14.162 and 13.650 respectively over a lifetime.  Therefore, at one year Rituximab 
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confers QALY benefits over mPR but this is reversed by five-years and continues over a 
lifetime.   
 
Incremental Net Monetary Benefit 
At one-year, five-year and ten-year post treatment the incremental net monetary benefit 
(INMB) of Rituximab therapy is £785.44, £1,071.86 and £386.32 respectively, indicating 
Rituximab is more cost-effective.  Over a lifetime the INMB is -£4,998.79 showing mPR is the 
more cost-effective option.  See table 6. 
 
Deterministic Sensitivity Analysis 
Constrained to address outcomes with a mixed-protocol Rituximab analysis the sensitivity 
analysis confirms that a major driver of cost for Rituximab was the number of infusions 
required.  The original four-dose regime is too expensive at five-years post treatment but for 
the B cell titrating regime and the regime described by Dahan et al27, at five-years post 
treatment, Rituximab is the cost-effective option.  The other major drivers of cost-
effectiveness in the Rituximab arm were death rate and the probability of reaching remission.     
For the mPR arm the main driver of the cost appears to be the frequency of infusions with 
removal of the cost of IV methylprednisolone resulting in the mPR being more cost-effective 
at five-years post treatment.  The use of pulsed monthly IV cyclophosphamide alongside daily 
oral Prednisolone (again without IV Methylprednisolone) also resulted in the mPR being the 
most cost-effective at five-years post treatment.  See figure 3 for full tornado plot of sensitivity 
analysis.  
 
Cost effectiveness acceptability curve 
Figure 4 - CEAC for the comparison based on the 10,000 PSA simulations.  It shows the 
likelihood that Rituximab is cost-effective compared to mPR over a range of willingness-to-
pay (WTP) per QALY gain threshold values (Lambda).  At a lambda of £20,000 Rituximab has a 
64% chance of being the cost-effective option at five-years post treatment. At a threshold of 
£30,000 this falls to 61%.  This reflects the fact that Rituximab is the cheaper option at this 
time point but with a slightly reduced QALY. 
 
 
 
Threshold analysis 
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In order for Rituximab to be the most cost-effective option over a lifetime, threshold analysis 
shows that the transition probability for treatment to active disease, partial remission and 
complete remission would have to change from 0.51250 to 0.61706, from 0.28500 to 0.22387 
and from 0.20250 to 0.15907 respectively.  Alternatively, the transition probability for active 
disease to death and partial remission to death for Rituximab would have to change from 
0.00315 to 0.00136 and from 0.00680 to 0.00225 respectively. 
Threshold analysis to determine the cost at which Rituximab represents the cost-effective 
option over a lifetime showed that due to the disparity in QoL there is no price at which it is 
cost-effective over a lifetime. 
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Discussion  
The NHS, as with healthcare systems around the world, endeavours to provide the best care 
possible, with limited resources, for its aging population and increasingly complex patients.  
This has resulted in NICE, the regulatory body, considering not only the health benefits of 
therapies but also their economic impact.   
Rituximab has become increasingly important in the treatment of a range of autoimmune 
conditions48-58.  Its attraction lies in its more directed immunoregulation and reduced side 
effect profile as compared to other immunosuppressants.  Its single dose cost however, has 
limited its use in conditions such as MN, especially where there is a paucity of evidence from 
RCTs available. 
With this lack of RCTs but with good evidence that Rituximab can provide a benefit for patients 
in a number of trials and case series24-28, we constructed a Markov model to assess its cost-
effectiveness when compared to the standard of care, i.e. the mPR.  Using costs from the UK 
NHS we found that at every time point analysed Rituximab was the cheapest option and this 
was especially true if using the B-cell titration regime.  At one year post-treatment, the QALY 
was better using Rituximab than the mPR, but over a life-time this reduced with the mPR 
providing an increment of approximately half a QALY.  However, Rituximab may still represent 
value for money given the cost savings are so high for every QALY lost. 
It appears that the main driver of cost for the mPR is the frequency of infusions, adding cost 
to an inexpensive medication such as Methylprednisolone.  This is also true for Rituximab, 
with the original regime, in which patients have four doses, proving less cost-effective25.  In 
the B-cell titration regime24, patients continue to have a good response to treatment but with 
fewer infusions making it consistently more cost-effective. 
The reduction in quality of life for Rituximab over time is in part associated with the slightly 
increased risk of death and to a lesser extent the higher risk of relapse after Rituximab.  Our 
model, however, is a conservative estimate for the quality of life benefits from Rituximab, as 
we do not take into account late complications associated with the therapies.  It is well 
documented that there is an increased risk of malignancy many years after treatment with 
Cyclophosphamide59.  Rituximab in contrast, appears to have fewer complications and no 
indication of an increased risk of malignancy.    Our model does not capture the quality of life 
associated with the provision of treatment, such as early onset side effects, notably nausea in 
cyclophosphamide, or with the number of visits.  With the reduced side effect profile and 
reduced hospital visits needed for Rituximab therapy one could deduce that this would 
contribute to an improved quality of life although this is not possible to prove in this model.    
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This is the most comprehensive estimate of the cost-effectiveness of treatment for PMN to 
date but it does come with limitations.  The spread of results on the scatterplot for the PSA at 
the lifetime horizon indicates significant uncertainty in the results with the robustness of data 
available degenerating over time.  This highlights the need for further good quality long-term 
prospective research comparing these therapies.  Another limitation is that this evaluation 
was based on a naive comparison, if other single arm or cohort study data becomes available 
it may be that an indirect comparison would then be feasible. 
Due to the paucity of RCTs investigating the efficacy of Rituximab in PMN we opted to base 
the Rituximab arm on the largest data series available for its use in this condition.  This is a 
prospective observational study with all the limitations this confers on the data such as patient 
selection and centre bias but it remains the most robust data available. 
This and the Jha study used to inform the model are international studies (Italy and India) but 
for precision our model is costed to the UK health system.  At present, there are no large-scale 
clinical trials published using Rituximab in a UK population, and there have been no large 
clinical trials in the UK using Cyclophosphamide for the treatment of PMN.  
Another limitation has been the assignment of utility values to the disease.  There is good 
validated data for population norms but renal specific quality of life data is scarce.  This meant 
for active disease and RRT we had to convert SF-36 scores to utility values using standard 
methods39-42.   
PMN can be a slowly progressing disease with many patients following a relapsing and 
remitting pattern over a number of years.  Here we used only the rates for transition to ESRD 
and RRT as described in the two papers.  This is likely to have underestimated the degree to 
which patients progressed to ESRD over a lifetime due to the relatively short follow up time 
of the studies.  Given the uncertainty already apparent in the model over a lifetime, it adds 
further evidence for the need for long term RCTs in PMN. 
This model has only included the cost of therapy at a tertiary level.  It was beyond the scope 
of the study to assess the overall societal cost and there is likely to be significant cost to 
patients, families and carers in the form of lost days of work, travel costs, equipment costs.  
The cost of primary healthcare contact has also not been included in this model. 
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Rituximab has shown promise as a therapy for PMN in a number of studies but the high cost 
of the medication has proven to be a barrier to its widespread acceptance.  Here we have 
constructed the most detailed economic model yet for the treatment of PMN and show that 
Rituximab is not more expensive than the gold standard treatment and is cheaper over a 
lifetime.  This work highlights the uncertainty surrounding PMN treatment with the small 
number of RCTs available to guide practitioners and commissioning bodies.  Based on the 
evidence available, the longer-term effectiveness of Rituximab in PMN needs further 
evaluation, and importantly, long-term trials comparing Rituximab with cyclophosphamide-
based therapy should be undertaken to help establish the most cost-effective management 
of the condition. 
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